| Author/Editor | Štrukelj, Borut | |
| Title | Biološka zdravila pri multipli sklerozi | |
| Translated title | Biological medicinal products in the treatment of multiple sclerosis | |
| Type | članek | |
| Vol. and No. | Letnik 66, št. 1 | |
| Publication year | 2015 | |
| Volume | str. 80-84 | |
| ISSN | 0014-8229 - Farmacevtski vestnik | |
| Language | slv | |
| Abstract | Biološka zdravila za zdravljenje multiple skleroze temeljijo na interakcijah med celicami imunskega sistema. Zdravili prvega izbora sta interferon-ß in glatiramer acetat, ki pa sta delno učinkovita le v prvi fazirazvoja multiple skleroze tipa RRMS (relapsing-remitting multiple sclerosis). V zadnjem desetletju so v razvoju ali že na tržišču specifične biološke učinkovine z imunosupresivnim delovanjem iz skupine monklonskih protiteles, kot so že registrirani natalizumab in alemtuzumab, v razvoju pa so še daclizumab, rituksimab, ocrelizumab in ofatumumab. Vzporedno pa raziskovalci preučujejo možnost uporabe matičnih celic, kakor tudi tehnologije RNK interference za zmanjšanje napredovanja oziroma za zdravljenje multiple skleroze.Therapeutic approaches to multiple sclerosis by means of modern biological medicinal products are based on altering the function of immune system. Interferon-ß and glatiramer acetate are basic biologicals in the treatment of RRMS ((relapsing-remitting multiple sclerosis) type of disease. Both biologicals are only partially suc- cesful, have important safety limitations and are effective in the earlier stages. Beside, monoclonal antibodies, suchas natalizumab, alemtuzumab, daclizumab, rituximab, ocrelizumab and of atumumab that act as specific and potent biological immunosupressive agents may offer considerable advantages over other biological and non-biological medicines. And finally, novel alternative methods, such as stem cell therapy or RNA interference therapy open a new frontier in the battle against the devastating effects of multiple sclerosis. | |
| Descriptors | Multipla skleroza Biološka zdravila | |
| Keywords | interferoni monoklonska protitelesa mikroRNK klinične študije farmakogenomika interferona ß1 |